The University of Colorado Denver | Anschutz Medical Campus, through the Institutional Biosafety Committee and the department of Environmental Health & Safety Biosafety division, is responsible for ensuring that activities involving recombinant DNA, select agents or toxins, infectious agents, and other biological hazards at the university are in compliance with established National Institutes of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, and all other applicable federal, state and local requirements.
Research Involving Recombinant DNA or Synthetic Nucleic Acids
The IBC reviews and approves all proposals that anticipate use of DNA material. IBC applications are submitted via email. Questions regarding research involving recombinant DNA should be directed to IBC@ucdenver.edu.
IBC Compliance Note: NIH Guidelines for Research Involving Recombinant DNA
The university requires that all use of recombinant DNA be registered with the Institutional Biosafety Committee. Many common uses of recombinant DNA, however, qualify for exemption under Section III-F of the NIH Guidelines. If recombinant DNA being used qualifies for an exemption under these criteria, the IBC application must still be submitted. After review, the IBC will provide an exemption decision. If any changes are made to protocols for a study that has received an exemption, an amendment must be submitted to the IBC.
If the recombinant DNA proposed for use does not meet any of the exemption criteria above, an application must be sumitted and undergo a full review by the IBC.
These programs are in place to assist with the management of: